Division of Hematology and Oncology

W. Kimryn Rathmell, M.D., Ph.D., Alexander Professor for Translational Science and associate director for Training and Education at Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, has been named director of Vanderbilt’s Division of Hematology and Oncology.

Carrie Kitko, M.D., has joined Monroe Carell Jr. Children’s Hospital at Vanderbilt as associate professor of Pediatrics and director of the Pediatric Stem Cell Transplant Program in the Division of Hematology/Oncology.

A new mouse model demonstrates that the Hhex gene – which is linked to blood cancers – is critical for normal blood cell production.

Melanoma patients whose tumors test positive for mutations in the NRAS gene were more likely to benefit from new immunotherapy drugs, according to a new study led by Vanderbilt-Ingram Cancer Center (VICC) investigators.

A group of Vanderbilt-led investigators has identified a new gene mutation that may explain why some breast cancer patients do not respond to anti-hormone therapy.

The grants, which total $830,000, are part of the non-profit organization’s commitment to young scientists, as well as established investigators who are searching for more effective breast cancer therapies.

A Vanderbilt lung cancer patient’s exceptional response to different types of therapies spurred research that suggests lung cancer patients with specific gene alterations may benefit from combination therapy that targets two different cancer pathways.